Pharmaceutical research provider Tigermed co-led a round sized at nearly $71m for the cancer drug developer, which was spun off from Eddingpharm.

China-based oncology product developer EOC Pharma has raised almost RMB500m ($71m) in a series C round co-led by contract research organisation Tigermed, DealStreetAsia reported today. Venture capital firm TF Capital and investment firm Yingke PE co-led the round, which included Hanne Capital and Everest Venture Capital Investment. Life Venture was financial adviser on the deal.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.